4D Molecular Therapeutics (NASDAQ:FDMT) Earns Buy Rating from HC Wainwright
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $36.00 target price on the stock. Several other equities analysts have also commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on […]
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $36.00 target price on the stock. Several other equities analysts have also commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on […]
